Bioxytran, Inc. (BIXT)

Bioxytran Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	0.51	0.01	0.03	0.3	0.07
Cash & Short-Term Investments	0.51	0.01	0.03	0.3	0.07
Cash Growth	9793.56%	-80.24%	-91.17%	308.25%	73.57%
Other Current Assets	0	-	-	-	-
Total Current Assets	0.51	0.01	0.03	0.3	0.07
Long-Term Deferred Charges	0.15	0.13	0.11	0.08	0.05
Total Assets	0.66	0.14	0.14	0.37	0.12
Accounts Payable	0.02	0.01	0	0	-
Accrued Expenses	1.48	0.41	0.3	1.46	1.16
Short-Term Debt	1.25	1.09	1.93	2.17	2.12
Other Current Liabilities	0.5	0.41	1.01	0.04	-
Total Current Liabilities	3.25	1.93	3.24	3.66	3.28
Total Liabilities	3.25	1.93	3.24	3.66	3.28
Common Stock	0.11	0.09	0.14	0.12	0.11
Additional Paid-In Capital	18.3	17	13.09	8.39	5.88
Retained Earnings	-21.04	-18.92	-15.7	-11.22	-8.75
Comprehensive Income & Other	-	-	0.05	-	-
Total Common Equity	-2.63	-1.84	-2.42	-2.7	-2.76
Minority Interest	-	-	-0.68	-0.59	-0.4
Shareholders' Equity	-2.59	-1.79	-3.1	-3.29	-3.16
Total Liabilities & Equity	0.66	0.14	0.14	0.37	0.12
Total Debt	1.25	1.09	1.93	2.17	2.12
Net Cash (Debt)	-0.74	-1.09	-1.9	-1.87	-2.05
Net Cash Per Share	-0.01	-0.01	-0.01	-0.02	-0.02
Filing Date Shares Outstanding	113.36	88.88	166.49	123.5	110.84
Total Common Shares Outstanding	108.15	86.78	145.64	123.25	110.84
Working Capital	-2.74	-1.93	-3.22	-3.37	-3.21
Book Value Per Share	-0.02	-0.02	-0.02	-0.02	-0.02
Tangible Book Value	-2.63	-1.84	-2.42	-2.7	-2.76
Tangible Book Value Per Share	-0.02	-0.02	-0.02	-0.02	-0.02

Source: S&P Global Market Intelligence. Standard template. Financial Sources.